News|Articles|November 19, 2026

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Listen
0:00 / 0:00

Key Takeaways

  • Mid-term guidance reset to ~5% CAGR at constant currencies for 2026–2031, with management explicitly assuming no large acquisitions and leaning on 10 late-stage programs for durability.
  • Pipeline risk was highlighted by two late-stage failures and a $2.2B impairment, including del-desiran from the Avidity deal, despite reiterated multibillion-dollar peak sales expectations.
SHOW MORE

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

Novartis trimmed its mid-term sales growth outlook at its annual “Meet Novartis Management” event in London on Wednesday,1 projecting net sales growth of approximately 5% annually at constant currencies from 2026 through 2031—the low end of a prior range of 5% to 6% set for 2025 to 2030. Shares fell roughly 3% on the news, though the Swiss drugmaker’s stock remains up about 16% for the year.

The narrowed target reflects pressure from patent expirations and two significant late-stage clinical trial failures earlier in 2026, which prompted a $2.2 billion writedown in the third quarter. Among the setbacks was del-desiran, a muscle-disorder asset acquired through Novartis’s $12 billion Avidity Biosciences deal—a transaction that has drawn heightened scrutiny of CEO Vas Narasimhan’s acquisition strategy. The company said it is reviewing next steps for del-desiran and still expects multibillion-dollar peak sales from the program.

Narasimhan sought to reassure investors that the pipeline can sustain growth beyond the current decade. “Most of the growth beyond 2031 will come from internally developed medicines,” he said at the event. The company said its targets assume no large acquisitions and pointed to 10 medicines currently in late-stage development as the foundation for continued expansion.

In a previously published conversation with Pharmaceutical Executive, Norstella VP Dan Chancellor of thought leadership discussed the industry’s changing attitudes towards innovation and early-stage development. “The industry isn’t losing its ability to innovate, but rather what we're seeing is much tighter selectivity earlier on. Companies are choosing to advance fewer candidates, but holding them to a higher bar before they commit real money downstream,” he said.

Despite the lower headline growth number, Novartis raised its peak sales forecasts for three key franchises. Kesimpta, the company’s multiple sclerosis therapy, now carries a peak sales target of $8 billion, up from $6 billion. Scemblix, its treatment for chronic myeloid leukemia, was raised to $5 billion from $4 billion, and cardiovascular drug Leqvio received an identical upgrade to $5 billion. The company also maintained its projection that core operating income margins will return above 40% by 2029.

The market reaction underscored investor unease with Novartis’s near- and medium-term growth narrative. The loss of exclusivity for top-selling heart failure drug Entresto—which is already losing ground to generics and is expected to shed roughly $4 billion in sales this year—looms large over the company’s near-term numbers. Analysts also anticipate growing pricing pressure on breast cancer blockbuster Kisqali and immunology stalwart Cosentyx as cheaper alternatives emerge toward the end of the decade.

Portfolio manager Daniel Bolanowski said the selloff reflected an “absence of anything revolutionary” in the updated guidance,2 adding that his deeper concern is Novartis’s growth trajectory after 2031. Analyst Urban Fritsche of Zürcher Kantonalbank described the 5% target as fair but characterized the investment case as a “show me” story, contingent on positive clinical data from the late-stage pipeline.

The broader analyst consensus sits at approximately 4.5% annual growth for the 2026 to 2031 period, slightly below the company’s own projection, with expectations for a meaningful deceleration after 2030 as patent cliffs deepen.

Wednesday’s event also featured an AI panel session, underscoring Novartis’s continued effort to position artificial intelligence as a strategic lever in drug discovery and development—a theme Narasimhan has championed across multiple investor forums.

Novartis will face its next major test of investor confidence as clinical readouts from its 10 late-stage programs begin to trickle in over the coming quarters, with the pipeline increasingly viewed as the decisive factor in whether the company can sustain growth into the 2030s.

Sources

  1. Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last CNBC November 19, 2026 https://www.cnbc.com/2026/11/19/novartis-stock-cmd-2026-ceo.html
  2. Novartis trims medium-term growth target, shares fall Market Screener November 19, 2026 https://www.marketscreener.com/news/novartis-narrows-mid-term-annual-sales-growth-target-to-5-through-2031-ce785eddd18df52d

Related to this article